share_log

There May Be Underlying Issues With The Quality Of ShanXi C&Y Pharmaceutical GroupLTD's (SZSE:300254) Earnings

There May Be Underlying Issues With The Quality Of ShanXi C&Y Pharmaceutical GroupLTD's (SZSE:300254) Earnings

山西證券供股(SZSE:300254)藥品集團有限公司的盈利可能存在潛在問題
Simply Wall St ·  10/30 16:15

ShanXi C&Y Pharmaceutical Group Co.,LTD.'s (SZSE:300254) robust earnings report didn't manage to move the market for its stock. Our analysis suggests that shareholders have noticed something concerning in the numbers.

山西中醫藥業集團股份有限公司(SZSE:300254)強勁的盈利報告未能推動其股票市場。我們的分析表明,股東對數字中注意到了一些令人擔憂的事情。

big
SZSE:300254 Earnings and Revenue History October 30th 2024
SZSE:300254 盈利和營業收入歷史 2024年10月30日

How Do Unusual Items Influence Profit?

非常規項目如何影響利潤?

Importantly, our data indicates that ShanXi C&Y Pharmaceutical GroupLTD's profit received a boost of CN¥49m in unusual items, over the last year. While it's always nice to have higher profit, a large contribution from unusual items sometimes dampens our enthusiasm. When we crunched the numbers on thousands of publicly listed companies, we found that a boost from unusual items in a given year is often not repeated the next year. And that's as you'd expect, given these boosts are described as 'unusual'. We can see that ShanXi C&Y Pharmaceutical GroupLTD's positive unusual items were quite significant relative to its profit in the year to September 2024. All else being equal, this would likely have the effect of making the statutory profit a poor guide to underlying earnings power.

重要的是,我們的數據顯示,山西中醫藥業集團有限公司的利潤在過去一年中因異常項目獲得了人民幣4900萬的提升。雖然盈利增加總是令人高興的,但來自異常項目的大幅貢獻有時會減弱我們的熱情。當我們對數千家上市公司的數據進行分析後,發現在某一年中由異常項目帶來的提振通常不會在下一年重複。這是出乎意料的,因爲這些提振被描述爲「異常」。我們可以看到,相對於2024年9月份的利潤,山西中醫藥業集團的正面異常項目相當顯著。其他條件不變的情況下,這可能會導致使法定利潤成爲衡量基礎盈利能力的不良指標。

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of ShanXi C&Y Pharmaceutical GroupLTD.

注意:我們始終建議投資者檢查資產負債表的強壯程度。 點擊這裏查看我們對山西中醫藥業集團有限公司資產負債表的分析。

Our Take On ShanXi C&Y Pharmaceutical GroupLTD's Profit Performance

關於山西中醫藥業集團有限公司盈利表現的看法

As we discussed above, we think the significant positive unusual item makes ShanXi C&Y Pharmaceutical GroupLTD's earnings a poor guide to its underlying profitability. For this reason, we think that ShanXi C&Y Pharmaceutical GroupLTD's statutory profits may be a bad guide to its underlying earnings power, and might give investors an overly positive impression of the company. The good news is that it earned a profit in the last twelve months, despite its previous loss. At the end of the day, it's essential to consider more than just the factors above, if you want to understand the company properly. So while earnings quality is important, it's equally important to consider the risks facing ShanXi C&Y Pharmaceutical GroupLTD at this point in time. For example, we've discovered 2 warning signs that you should run your eye over to get a better picture of ShanXi C&Y Pharmaceutical GroupLTD.

正如我們之前討論的那樣,我們認爲顯著的正飛凡項目使得山西C&Y藥品集團有限公司的收益不是其潛在盈利能力的良好指引。因此,我們認爲山西C&Y藥品集團有限公司的的法定利潤可能不是其潛在盈利能力的良好指引,可能給投資者過分樂觀的印象。好消息是,儘管之前虧損,它在過去十二個月中取得了盈利。歸根結底,如果您想正確了解公司,不僅需要考慮上述因素,而且需要考慮更多其他因素。因此,儘管收益質量很重要,但同樣重要的是考慮目前山西C&Y藥品集團有限公司面臨的風險。例如,我們發現了2個警示信號,您應該仔細查看,以更好地了解山西C&Y藥品集團有限公司。

Today we've zoomed in on a single data point to better understand the nature of ShanXi C&Y Pharmaceutical GroupLTD's profit. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.

今天,我們聚焦一個單一數據點,以更好地了解山西C&Y藥品集團有限公司利潤的性質。但還有很多其他方法可以幫助您了解一家公司。例如,許多人將股本回報率視爲有利的業務經濟指標,而其他人則喜歡「跟隨資金」並尋找內部人員正在購買的股票。因此,您可能希望查看此處免費收集的擁有高股本回報率的公司,或者此列表中擁有高內部持股的股票。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接與我們聯繫。或者,發送電子郵件至editorial-team @ simplywallst.com。
Simply Wall St的這篇文章是一般性質的。我們僅基於歷史數據和分析師預測提供評論,使用公正的方法,我們的文章並非意在提供財務建議。這並不構成買入或賣出任何股票的建議,並且不考慮您的目標或財務狀況。我們旨在爲您帶來基於基礎數據驅動的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St對提及的任何股票都沒有持倉。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論